Portal de Periódicos da CAPES

Lipoprotein abnormalities and their consequences for patients with Type 2 diabetes

2003; Wiley; Volume: 5; Issue: s1 Linguagem: Inglês

10.1046/j.1462-8902.2003.0310.x

1463-1326

Andrew J. Krentz,

Lipid metabolism and disorders

Diabetes, Obesity and MetabolismVolume 5, Issue s1 p. s19-s27 Lipoprotein abnormalities and their consequences for patients with Type 2 diabetes Andrew J Krentz, Corresponding Author Andrew J Krentz Southampton General Hospital, Southampton, UK *Dr Andrew J. Krentz, Southampton General Hospital, Southampton SO16 6YD, UK. E-mail:[email protected]Search for more papers by this author Andrew J Krentz, Corresponding Author Andrew J Krentz Southampton General Hospital, Southampton, UK *Dr Andrew J. Krentz, Southampton General Hospital, Southampton SO16 6YD, UK. E-mail:[email protected]Search for more papers by this author First published: 22 October 2003 https://doi.org/10.1046/j.1462-8902.2003.0310.xCitations: 132Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570–2581. 2 Stephenson JM, Kenny S, Stevens LK et al. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 1995; 12: 149–155. 3 Yudkin JS. Managing the diabetic patient with acute myocardial infarction. Diabet Med 1998; 15: 276–281. 4 Krentz AJ. Type 2 diabetes and atherosclerotic cardiovascular disease: do they share common antecedents? Br J Diabetes Vasc Dis 2002; 2: 370–378. 5 Coutinho M, Gerstein H, Wang Y et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233–240. 6 Khaw KT, Wareham N, Luben R et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001; 322: 15. 7 UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853. 8 UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865. 9 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 1999; 317: 703–713. 10 UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes. BMJ 1998; 317: 713–720. 11 Krentz AJ. UKPDS and beyond: into the next millennium. Diabetes Obes Metab 1999; 1: 13–22. 12 Yudkin JS. The United Kingdom Prospective Diabetes Study – everything you needed to know about diabetes but were afraid to ask. European Heart J 1999; 20: 781–783. 13 Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in Type 2 diabetes mellitus. In: AJ Krentz, eds. Drug Treatment of Type 2 Diabetes. Auckland, New Zealand: Adis International, 2000, 61–76. 14 Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453–458. 15 Krentz AJ. Insulin Resistance. Oxford: Blackwell Science, 2002. 16 Wallace T, Matthews D. The assessment of insulin resistance in man. Diabetic Med 2002; 19: 527–534. 17 Krentz AJ, Singh BM, Nattrass M. Impaired glucose tolerance is characterized by multiple abnormalities in the regulation of intermediary metabolism. Diabet Med 1991; 8: 848–854. 18 Howard G, O'Leary DH, Zaccaro D et al. Insulin sensitivity and atherosclerosis. Circulation 1996; 93: 1809–1817. 19 Frayn KN. Insulin resistance and lipid metabolism. Current Opinion Lipidol 1993; 4: 197–204. 20 Reaven GM. The fourth musketeer – from Alexandre Dumas to Claude Bernard. Diabetologia 1995; 38: 3–13. 21 Gibbons GF, Islam K, Pease RJ. Mobilisation of triacylglycerol stores. Biochim Biophys Acta 2000; 1483: 37–57. 22 Singh BM, Krentz AJ, Nattrass M. Insulin resistance in the regulation of lipolysis and ketone body metabolism in non-insulin dependent diabetes is apparent at very low insulin concentrations. Diabetes Res Clin Pract 1993; 20: 55–62. 23 Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000; 49: 883–888. 24 Byrne CD, Wareham NJ, Day NE et al. Decreased non-esterified fatty acid suppression and features of the insulin resistance syndrome occur in a subgroup of individuals with normal glucose tolerance. Diabetologia 1995; 38: 1358–1366. 25 Taskinen M-R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733–749. 26 Malmström R, Packard CJ, Watson TDG et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 1997; 17: 1454–1464. 27 Malmström R, Packard CJ, Caslake M et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997; 40: 454–462. 28 Turner RC, Millns H, Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998; 316: 823–828. 29 Haffner SM. Management of dyslipidaemia in adults with diabetes. Diabetes Care 1998; 21: 160–178. 30 Taguchi S, Oinuma T, Yamada T. A comparative study of cultured smooth muscle cell proliferation and injury, utilizing glycated low density lipoproteins with slight oxidation, auto-oxidation, or extensive oxidation. J Atheroscler Thromb 2000; 7: 132–137. 31 Miller M. Is hypertriglyceridaemia an independent risk factor for coronary heart disease? European Heart J 1998; Suppl. H: H18–H22. 32 Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497. 33 Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta- analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–219. 34 Syvänne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997; 5 (Suppl. 1): S120–S123. 35 Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992; 70: 733–737. 36 Ballantyne CM, Olsson AG, Cook TJ et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104: 3046–3051. 37 Scandinavian Simvastatin Survival Study (4 S) Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383–1389. 38 Mills JD, Grant PJ. Insulin resistance, haemostatic factors and cardiovascular risk. Br J Diabetes Vasc Dis 2002; 2: 19–26. 39 Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999; 246: 341–355. 40 Burnett JR, Watts GF. Therapeutic considerations of postprandial dyslipidaemia. Diabetes Obes Metab 2001; 3: 143–156. 41 Teno S, Uto Y, Nagashima H et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with Type 2 diabetes. Diabetes Care 2000; 23: 1401–1406. 42 Durrington PN, Sniderman A. Hyperlipidaemia. Oxford: Health Press, 2002. 43 American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 179–182. 44 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22. 45 Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079–1082. 46 Department of Health. National Service Framework for Coronary Heart Disease. London, UK: Stationery Office, 2000. 47 National Institute for Clinical Excellence. Management of Type 2 Diabetes: Management of Blood Pressure and Blood Lipids (Inherited Clinical Guideline H). London, UK: National Health Service, 2002. 48 Wood D, Durrington P, Poulter N et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl. 2): S1–S29. 49 Martens FM, Visseren FL, Lemay J et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62: 1463–1480. 50 Glass GK. Antiatherogenic effects of thiazolidinediones? Arterioscler Thromb Vasc Biol 2001; 21: 295–296. 51 Pyorala K, Pedersen TR, Kjekshus J et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614–20. 52 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–2016. 53 Sever P, Dahlof B, Poulter N et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–1158. 54 Colhoun HM, Thomason MJ, Mackness MI et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Med 2002; 19: 201–211. 55 CARDS atorvastatin in diabetes trial halted early. Prac Diabetes Int 2003; 20: 230. Citing Literature Volume5, Issues1November 2003Pages s19-s27 ReferencesRelatedInformation